Education
About Us
Working with TipRanks
Follow Us
AlphaTON Capital (ATON)
NASDAQ:ATON
Top Page
AlphaTON Capital
(NASDAQ:ATON)
Select Model
Select Model
Rating:48Neutral
Price Target:―
Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock's attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.
AlphaTON Capital (ATON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.83M
Dividend YieldN/A
Average Volume (3M)79.76K
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue GrowthN/A
EPS Growth48.91%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,278,622
10 Day Avg. Volume126,578
30 Day Avg. Volume79,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AlphaTON Capital Business Overview & Revenue Model
Company DescriptionPortage Biotech Inc. (PRTG) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company operates primarily in the health care sector, specifically targeting the treatment of cancer through its proprietary platform technologies and a robust pipeline of novel therapeutics. Portage Biotech aims to enhance the body's immune response to fight cancer, offering potential breakthroughs in cancer treatment.
How the Company Makes MoneyPortage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.
AlphaTON Capital Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
AlphaTON Capital Technical Analysis
Neutral
6.30
Price Trends
6.84
Negative
7.10
Negative
6.20
Positive
Market Momentum
-0.38
Negative
47.95
Neutral
63.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATON, the sentiment is Neutral. The current price of 6.3 is below the 20-day moving average (MA) of 6.32, below the 50-day MA of 6.84, and above the 200-day MA of 6.20, indicating a neutral trend. The MACD of -0.38 indicates Negative momentum. The RSI at 47.95 is Neutral, neither overbought nor oversold. The STOCH value of 63.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATON.
AlphaTON Capital Risk Analysis
AlphaTON Capital disclosed 28 risk factors in its most recent earnings report. AlphaTON Capital reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We rely on information technology and security systems and any damage, interruption or compromise of our information technology and security systems or data could disrupt and harm our business. Q1, 2023
2.
Any actual or perceived failure by us to comply with government or other obligations related to privacy or data protection could adversely affect our business. Q1, 2023
AlphaTON Capital Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | 15.19M | 0.84 | 72.91% | ― | -82.24% | 0.00% | |
52 Neutral | 11.49M | -0.67 | -89.16% | ― | -19.32% | 44.73% | |
49 Neutral | 9.90M | -0.28 | 0.00% | ― | 0.00% | -219.97% | |
48 Neutral | $13.83M | ― | ― | ― | 48.91% | ||
43 Neutral | 67.57M | -15.55 | 0.00% | ― | 186.84% | 89.16% | |
40 Underperform | 8.00M | -1.31 | -121.14% | ― | -1.88% | 23.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
ATON
AlphaTON Capital
6.30
-1.51
-19.33%
CANF
Can-Fite BioPharma
0.63
-1.41
-69.12%
PHIO
Phio Pharmaceuticals
2.24
-1.19
-34.69%
CLRB
Cellectar Biosciences
5.50
-54.20
-90.79%
MTVA
MetaVia
1.03
-2.16
-67.71%
BOLT
Bolt Biotherapeutics
5.34
-7.16
-57.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.